1 min read
Add as a preferred source on Google

Stipple Bio Announces Lilly Cancer Deal Valued at Up to $5.9 Billion

Stipple Bio announced the exclusive worldwide agreement on Nov. 16.

Gloved hands examine a cell culture dish in a laboratory / TokenPost.ai
Gloved hands examine a cell culture dish in a laboratory / TokenPost.ai

Stipple Bio announced Nov. 16 that it entered an exclusive worldwide oncology licensing agreement with Eli Lilly and Company.

The licensing deal is valued at up to $5.9 billion.

Stipple Bio is based in Cambridge, Massachusetts.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…